Search

Your search keyword '"Sise, Meghan E."' showing total 520 results
Start Over Author "Sise, Meghan E."
520 results on '"Sise, Meghan E."'

2. AKI treated with kidney replacement therapy in critically Ill allogeneic hematopoietic stem cell transplant recipients

Author

Kim, Helena, Ali, Rafia, Short, Samuel, Kaunfer, Sarah, Krishnamurthy, Shobana, Durai, Lavanya, Yilmam, Osman, Shenoy, Tushar, Monson, Audrey E., Thomas, Charlotte, Park, Isabel, Martini, Dylan, Newcomb, Richard, Shapiro, Roman M., Soiffer, Robert J., DeFilipp, Zachariah, Baron, Rebecca M., Gupta, Shruti, Sise, Meghan E., and Leaf, David E.

Published
2024
Full Text
View/download PDF

4. Corrigendum: Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis

Author

Moledina, Dennis G., Obeid, Wassim, Smith, Rex N., Rosales, Ivy, Sise, Meghan E., Moeckel, Gilbert, Kashgarian, Michael, Kuperman, Michael, Campbell, Kirk N., Lefferts, Sean, Meliambro, Kristin, Bitzer, Markus, Perazella, Mark A., Luciano, Randy L., Pober, Jordan S., Cantley, Lloyd G., Colvin, Robert B., Wilson, F. Perry, and Parikh, Chirag R.

Subjects
Proteins, Kidney diseases -- Diagnosis, Health care industry
Abstract

In the abstract and the legend for Figure 1, the descriptions of the Olink Proteomics assays utilized were incorrect. The correct descriptions appear below. The HTML and PDF versions of [...]

Published
2024
Full Text
View/download PDF

5. Acute kidney injury in patients treated with immune checkpoint inhibitors

Author

Gupta, Shruti, Short, Samuel AP, Sise, Meghan E, Prosek, Jason M, Madhavan, Sethu M, Soler, Maria Jose, Ostermann, Marlies, Herrmann, Sandra M, Abudayyeh, Ala, Anand, Shuchi, Glezerman, Ilya, Motwani, Shveta S, Murakami, Naoka, Wanchoo, Rimda, Ortiz-Melo, David I, Rashidi, Arash, Sprangers, Ben, Aggarwal, Vikram, Malik, A Bilal, Loew, Sebastian, Carlos, Christopher A, Chang, Wei-Ting, Beckerman, Pazit, Mithani, Zain, Shah, Chintan V, Renaghan, Amanda D, De Seigneux, Sophie, Campedel, Luca, Kitchlu, Abhijat, Shin, Daniel Sanghoon, Rangarajan, Sunil, Deshpande, Priya, Coppock, Gaia, Eijgelsheim, Mark, Seethapathy, Harish, Lee, Meghan D, Strohbehn, Ian A, Owen, Dwight H, Husain, Marium, Garcia-Carro, Clara, Bermejo, Sheila, Lumlertgul, Nuttha, Seylanova, Nina, Flanders, Lucy, Isik, Busra, Mamlouk, Omar, Lin, Jamie S, Garcia, Pablo, Kaghazchi, Aydin, Khanin, Yuriy, Kansal, Sheru K, Wauters, Els, Chandra, Sunandana, Schmidt-Ott, Kai M, Hsu, Raymond K, Tio, Maria C, Mothi, Suraj Sarvode, Singh, Harkarandeep, Schrag, Deborah, Jhaveri, Kenar D, Reynolds, Kerry L, Cortazar, Frank B, Leaf, David E, Salem, Joe-Elie, Bagnis, Corinne Isnard, Rahma, Osama E, Mothi, Suraj S, Selamet, Umut, Chang, Weiting, Hirsch, Jamie S, Sakhiya, Vipulbhai, Stalbow, Daniel, Wu, Sylvia, Cennamo, Armando, Papa, Sophie, Rigg, Anne, Shaunak, Nisha, Kibbelaar, Zoe A, and Benesova, Karolina

Subjects
Kidney Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Renal and urogenital, Good Health and Well Being, Acute Kidney Injury, Aged, Cohort Studies, Female, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Male, Middle Aged, Risk Factors, immunotherapy, CTLA-4 antigen, programmed cell death 1 receptor, ICPi-AKI Consortium Investigators
Abstract

BackgroundImmune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer.MethodsWe collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI.ResultsICPi-AKI occurred at a median of 16 weeks (IQR 8-32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3-10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI.ConclusionsPatients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.

Published
2021

6. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant

Author

Murakami, Naoka, Mulvaney, Patrick, Danesh, Melissa, Abudayyeh, Ala, Diab, Adi, Abdel-Wahab, Noha, Abdelrahim, Maen, Khairallah, Pascale, Shirazian, Shayan, Kukla, Aleksandra, Owoyemi, Itunu O, Alhamad, Tarek, Husami, Samir, Menon, Madhav, Santeusanio, Andrew, Blosser, Christopher D, Zuniga, Sandra Carias, Soler, Maria Jose, Moreso, Francesc, Mithani, Zain, Ortiz-Melo, David, Jaimes, Edgar A, Gutgarts, Victoria, Lum, Erik, Danovitch, Gabriel M, Cardarelli, Francesca, Drews, Reed E, Bassil, Claude, Swank, Jennifer L, Westphal, Scott, Mannon, Roslyn B, Shirai, Keisuke, Kitchlu, Abhijat, Ong, Song, Machado, Shana M, Mothi, Suraj S, Ott, Patrick A, Rahma, Osama, Hodi, F Stephen, Sise, Meghan E, Gupta, Shruti, Leaf, David E, Devoe, Craig E, Wanchoo, Rimda, Nair, Vinay V, Schmults, Chrysalyne D, Hanna, Glenn J, Sprangers, Ben, Riella, Leonardo V, Jhaveri, Kenar D, and Consortium, Immune Checkpoint Inhibitors in Solid Organ Transplant

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Organ Transplantation, Kidney Disease, Transplantation, Cancer, Rare Diseases, Clinical Research, Prevention, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.4 Surgery, Renal and urogenital, Carcinoma, Squamous Cell, Humans, Immune Checkpoint Inhibitors, Kidney Transplantation, Prospective Studies, Retrospective Studies, Skin Neoplasms, immune checkpoint inhibitors, kidney transplant, onconephrology, rejection, Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium, Urology & Nephrology, Clinical sciences
Abstract

Immune checkpoint inhibitors (ICIs) are widely used for various malignancies. However, their safety and efficacy in patients with a kidney transplant have not been defined. To delineate this, we conducted a multicenter retrospective study of 69 patients with a kidney transplant receiving ICIs between January 2010 and May 2020. For safety, we assessed the incidence, timing, and risk factors of acute graft rejection. For efficacy, objective response rate and overall survival were assessed in cutaneous squamous cell carcinoma and melanoma, the most common cancers in our cohort, and compared with stage-matched 23 patients with squamous cell carcinoma and 14 with melanoma with a kidney transplant not receiving ICIs. Following ICI treatment, 29 out of 69 (42%) patients developed acute rejection, 19 of whom lost their allograft, compared with an acute rejection rate of 5.4% in the non-ICI cohort. Median time from ICI initiation to rejection was 24 days. Factors associated with a lower risk of rejection were mTOR inhibitor use (odds ratio 0.26; 95% confidence interval, 0.09-0.72) and triple-agent immunosuppression (0.67, 0.48-0.92). The objective response ratio was 36.4% and 40% in the squamous cell carcinoma and melanoma subgroups, respectively. In the squamous cell carcinoma subgroup, overall survival was significantly longer in patients treated with ICIs (median overall survival 19.8 months vs. 10.6 months), whereas in the melanoma subgroup, overall survival did not differ between groups. Thus, ICIs were associated with a high risk of rejection in patients with kidney transplants but may lead to improved cancer outcomes. Prospective studies are needed to determine optimal immunosuppression strategies to improve patient outcomes.

Published
2021

7. Therapeutic advances in COVID-19

Author

Murakami, Naoka, Hayden, Robert, Hills, Thomas, Al-Samkari, Hanny, Casey, Jonathan, Del Sorbo, Lorenzo, Lawler, Patrick R., Sise, Meghan E., and Leaf, David E.

Published
2023
Full Text
View/download PDF

9. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

Author

Martin, Paul, Awan, Ahmed A., Berenguer, Marina C., Bruchfeld, Annette, Fabrizi, Fabrizio, Goldberg, David S., Jia, Jidong, Kamar, Nassim, Mohamed, Rosmawati, Pessôa, Mário Guimarães, Pol, Stanislas, Sise, Meghan E., Balk, Ethan M., Gordon, Craig E., Adam, Gaelen, Cheung, Michael, Earley, Amy, and Jadoul, Michel

Published
2022
Full Text
View/download PDF

13. Kidney Recovery and Death in Critically Ill Patients With COVID-19–Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study

Author

Gupta, Hsu, Faugno, Goyal, Raichoudhury, Tariq, Meyer, Sharma, Leaf, Kshirsagar, Walther, Carl P., Anumudu, Samaya J., Arunthamakun, Justin, Kopecky, Kathleen F., Milligan, Gregory P., McCullough, Peter A., Nguyen, Thuy-Duyen, Shaefi, Shahzad, Krajewski, Megan L., Shankar, Sidharth, Pannu, Ameeka, Valencia, Juan D., Bauer, Kenneth A., Waikar, Sushrut S., Kibbelaar, Zoe A., Athavale, Ambarish M., Hart, Peter, Upadhyay, Shristi, Vohra, Ishaan, Oyintayo, Ajiboye, Green, Adam, Rachoin, Jean-Sebastien, Schorr, Christa A., Shea, Lisa, Edmonston, Daniel L., Mosher, Christopher L., Shehata, Alexandre M., Cohen, Zaza, Allusson, Valerie, Bambrick-Santoyo, Gabriela, Bhatti, Noor ul aain, Mehta, Bijal, WilliamsSamantha K. Brenner, Aquino, Walters, Patricia, Go, Ronaldo C., Rose, Keith M., Hernán, Miguel A., Zhou, Amy M., Kim, Ethan C., Lisk, Rebecca, Chan, Lili, Mathews, Kusum S., Coca, Steven G., Altman, Deena R., Saha, Aparna, Soh, Howard, Wen, Huei Hsun, Bose, Sonali, Leven, Emily A., Wang, Jing G., Mosoyan, Gohar, Pattharanitima, Pattharawin, Gallagher, Emily J., Friedman, Allon N., Guirguis, John, Kapoor, Rajat, Meshberger, Christopher, Kelly, Katherine J., Parikh, Chirag R., Garibaldi, Brian T., Corona-Villalobos, Celia P., Wen, Yumeng, Menez, Steven, Malik, Rubab F., Cervantes, Carmen Elena, Gautam, Samir C., Mallappallil, Mary C., Ouyang, Jie, John, Sabu, Yap, Ernie, Melaku, Yohannes, Mohamed, Ibrahim, Bajracharya, Siddhartha, Puri, Isha, Thaxton, Mariah, Bhattacharya, Jyotsna, Wagner, John, Boudourakis, Leon, Nguyen, H. Bryant, Ahoubim, Afshin, Thomas, Leslie F., Sirganagari, Dheeraj Reddy, Guru, Pramod K., Kashani, Kianoush, Tehranian, Shahrzad, Zhou, Yan, Bergl, Paul A., Rodriguez, Jesus, Shah, Jatan A., Gupta, Mrigank S., Kumar, Princy N., Lazarous, Deepa G., Kassaye, Seble G., Melamed, Michal L., Johns. Ryan Mocerino, Tanya S., Prudhvi, Kalyan, Zhu, Denzel, Levy, Rebecca V., Azzi, Yorg, Fisher, Molly, Yunes, Milagros, Sedaliu, Kaltrina, Golestaneh, Ladan, Brogan, Maureen, Thakkar, Jyotsana, Kumar, Neelja, Ross, Michael J., Chang, Michael, Athreya, Akshay, Farag, Mohamed, Schenck, Edward J., Cho, Soo Jung, Plataki, Maria, Alvarez-Mulett, Sergio L., Gomez-Escobar, Luis G., Pan, Di, Lee, Stefi, Krishnan, Jamuna, Whalen, William, Charytan, David, Macina, Ashley, Srivastava, Anand, Leidner, Alexander S., Martinez, Carlos, Kruser, Jacqueline M., Wunderink, Richard G., Hodakowski, Alexander J., Velez, Juan Carlos Q., Price-Haywood, Eboni G., Matute-Trochez, Luis A., Hasty, Anna E., Mohamed, Muner M.B., Avasare, Rupali S., Zonies, David, Al-Samkari, Hanny, Leaf, Rebecca Karp, Rosovsky, Rachel, Sise, Meghan E., Newman, Erik T., Omar, Samah Abu, Pokharel, Kapil K., Sharma, Shreyak, Singh, Harkarandeep, Correa, Simon, Shaukat, Tanveer, Kamal, Omer, Wang, Wei, Lee, Meghan, Strohbehn, Ian A., Li, Jiahua, Mueller, Ariel L., Redfern, Roberta E., Cairl, Nicholas S., Naimy, Gabriel, Abu-Saif, Abeer, Hall, Danyell, Bickley, Laura, Rowan, Chris, Madhani-Lovely, Farah, Peev, Vasil, Reiser, Jochen, Byun, John J., Vissing, Andrew, Kapania, Esha M., Post, Zoe, Patel, Nilam P., Hermes, Joy-Marie, Sutherland, Anne K., Patrawalla, Amee, Finkel, Diana G., Danek, Barbara A., Arikapudi, Sowminya, Paer, Jeffrey M., Cangialosi, Peter, Liotta, Mark, Radbel, Jared, Puri, Sonika, Sunderram, Jag, Scharf, Matthew T., Ahmed, Ayesha, Berim, Ilya, Vatson, Jayanth S., Karp, George, Anand, Shuchi, Levitt, Joseph E., Garcia, Pablo, Boyle, Suzanne M., Song, Rui, Zhang, Jingjing, Woo, Sang Hoon, Deng, Xiaoying, Katz-Greenberg, Goni, Sharshir, Moh’d A., Rusnak, Vadym V., Bansal, Anip, Podoll, Amber S., Chonchol, Michel, Sharma, Sunita, Burnham, Ellen L., Rashidi, Arash, Hejal, Rana, Judd, Eric, Latta, Laura, Tolwani, Ashita, Albertson, Timothy E., Adams, Jason Y., Chang, Steven Y., Beutler, Rebecca M., Schulze, Carl E., Macedo, Etienne, RheeKa, Harin, thleen D. Liu, Jotwani, Vasantha K., Koyner, Jay L., Shah, Chintan V., Jaikaransingh, Vishal, Toth-Manikowski, Stephanie M., Joo, Min J., Lash, James P., Neyra, Javier A., Chaaban, Nourhan, Elias, Madona, Ahmad, Yahya, Dy, Rajany, Iardino, Alfredo, Au, Elizabeth H., Sosa, Marie Anne, Taldone, Sabrina, Contreras, Gabriel, De La Zerda, David, Gershengorn, Hayley B., Fornoni, Alessia, Hayek, Salim S., Blakely, Pennelope, Berlin, Hanna, Azam, Tariq U., Shadid, Husam, Pan, Michael, O’Hayer, Patrick, Meloche, Chelsea, Feroze, Rafey, Padalia, Kishan J., Leya, Jeff, Donnelly, John P., Admon, Andrew J., Flythe, Jennifer E., Tugman, Matthew J., Chang, Emily H., Brown, Brent R., Leonberg-Yoo, Amanda K., Spiardi, Ryan C., Miano, Todd A., Roche, Meaghan S., Vasquez, Charles R., Bansal, Amar D., Ernecoff, Natalie C., Kapoor, Sanjana, Verma, Siddharth, Chen, Huiwen, Kovesdy, Csaba P., Molnar, Miklos Z., Azhar, Ambreen, Hedayati, S. Susan, Nadamuni, Mridula V., Shastri, Shani, Willett, Duwayne L., Short, Samuel A.P., Renaghan, Amanda D., Enfield, Kyle B., Bhatraju, Pavan K., Malik, A. Bilal, Semler, Matthew W., Vijayan, Anitha, Joy, Christina Mariyam, Li, Tingting, Goldberg, Seth, Kao, Patricia F., Schumaker, Greg L., Christov, Marta, Griffiths, Jennifer, Gupta, Sanjeev, Kapoor, Aromma, Chugh, Savneek, Wilson, Perry, Arora, Tanima, Ugwuowo, Ugochukwu, Hsu, Caroline M., Gupta, Shruti, Tighiouart, Hocine, Goyal, Nitender, Faugno, Anthony J., Tariq, Asma, Raichoudhury, Ritesh, Sharma, Jill H., Meyer, Leah, Kshirsagar, Ravi K., Jose, Aju, Leaf, David E., and Weiner, Daniel E.

Published
2022
Full Text
View/download PDF

15. Early Renal Outcomes Following Heart Transplantation Using Organs Procured After Circulatory Death.

Author

Zhou, Joyce C., Sise, Meghan E., Drezek, Kamila, Wolfe, Stanley B., Osho, Asishana A., Prario, Monica N., Rabi, S. Alireza, Michel, Eriberto, Tsao, Lana, Coglianese, Erin, Doucette, Meaghan, Newton-Cheh, Christopher, Thomas, Sunu, Van-Khue Ton, Sutaria, Nilay, Schoenike, Mark W., Christ, Anastasia M., Paneitz, Dane C., Villavicencio, Mauricio, and Madsen, Joren C.

Published
2024
Full Text
View/download PDF

16. Identification of Immune Checkpoint Inhibitor–Induced Diabetes.

Author

Ruiz-Esteves, Karina N., Shank, Kaitlyn R., Deutsch, Aaron J., Gunturi, Alekhya, Chamorro-Pareja, Natalia, Colling, Caitlin A., Zubiri, Leyre, Perlman, Katherine, Ouyang, Tianqi, Villani, Alexandra-Chloé, Florez, Jose C., Gusev, Alexander, Reynolds, Kerry L., Miller, Karen K., Udler, Miriam S., Sise, Meghan E., and Rengarajan, Michelle

Published
2024
Full Text
View/download PDF

17. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis

Author

Moledina, Dennis G., Obeid, Wassim, Smith, Rex N., Rosales, Ivy, Sise, Meghan E., Moeckel, Gilbert, Kashgarian, Michael, Kuperman, Michael, Campbell, Kirk N., Lefferts, Sean, Meliambro, Kristin, Bitzer, Markus, Perazella, Mark A., Luciano, Randy L., Pober, Jordan S., Cantley, Lloyd G., Colvin, Robert B., Wilson, F. Perry, and Parikh, Chirag R.

Subjects
Nephritis -- Diagnosis -- Development and progression, Biological markers -- Physiological aspects -- Health aspects -- Identification and classification, Chemokines -- Physiological aspects -- Health aspects -- Identification and classification, Health care industry
Abstract

BACKGROUND. Acute tubulointerstitial nephritis (AIN) is one of the few causes of acute kidney injury with diagnosis- specific treatment options. However, due to the need to obtain a kidney biopsy for histological confirmation, AIN diagnosis can be delayed, missed, or incorrectly assumed. Here, we identify and validate urinary CXCL9, an IFN-[gamma]-induced chemokine involved in lymphocyte chemotaxis, as a diagnostic biomarker for AIN. METHODS. In a prospectively enrolled cohort with pathologist-adjudicated histological diagnoses, termed the discovery cohort, we tested the association of 180 immune proteins measured by an aptamer- based assay with AIN and validated the top protein, CXCL9, using sandwich immunoassay. We externally validated these findings in 2 cohorts with biopsy- confirmed diagnoses, termed the validation cohorts, and examined mRNA expression differences in kidney tissue from patients with AIN and individuals in the control group. RESULTS. In aptamer-based assay, urinary CXCL9 was 7.6-fold higher in patients with AIN than in individuals in the control group (P = 1.23 * [10.sup.-5]). Urinary CXCL9 measured by sandwich immunoassay was associated with AIN in the discovery cohort (n = 204; 15% AIN) independently of currently available clinical tests for AIN (adjusted odds ratio for highest versus lowest quartile: 6.0 [1.8-20]). Similar findings were noted in external validation cohorts, where CXCL9 had an AUC of 0.94 (0.86-1.00) for AIN diagnosis. CXCL9 mRNA expression was 3.9-fold higher in kidney tissue from patients with AIN (n = 19) compared with individuals in the control group (n = 52; P = 5.8 * [10.sup.-6]). CONCLUSION. We identified CXCL9 as a diagnostic biomarker for AIN using aptamer- based urine proteomics, confirmed this association using sandwich immunoassays in discovery and external validation cohorts, and observed higher expression of this protein in kidney biopsies from patients with AIN. FUNDING. This study was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awards K23DK117065 (DGM), K08DK113281 (KM), R01DK128087 (DGM), R01DK126815 (DGM and LGC), R01DK126477 (KNC), UH3DK114866 (CRP, DGM, and FPW), R01DK130839 (MES), and P30DK079310 (the Yale O'Brien Center). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health., Introduction Sudden loss of kidney function, termed acute kidney injury (AKI), is common, affecting 1 in 5 hospitalized patients and is associated with adverse long-term outcomes, including chronic kidney disease, [...]

Published
2023
Full Text
View/download PDF

18. Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation

Author

Molnar, Miklos Z., Potluri, Vishnu S., Schaubel, Douglas E., Sise, Meghan E., Concepcion, Beatrice P., Forbes, Rachel C., Blumberg, Emily, Bloom, Roy D., Shaffer, David, Chung, Raymond T., Strohbehn, Ian A., Elias, Nahel, Azhar, Ambreen, Shah, Mital, Sawinski, Deirdre, Binari, Laura A., Talwar, Manish, Balaraman, Vasanthi, Bhalla, Anshul, Eason, James D., Besharatian, Behdad, Trofe-Clark, Jennifer, Goldberg, David S., and Reese, Peter P.

Published
2022
Full Text
View/download PDF

19. Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study

Author

Gupta, Shruti, primary, Glezerman, Ilya G, additional, Hirsch, Jamie S, additional, Chen, Kevin L, additional, Devaraj, Nishant, additional, Wells, Sophia L, additional, Seitter, Robert H, additional, Kaunfer, Sarah A, additional, Jose, Arunima M, additional, Rao, Shreya P, additional, Ortega, Jessica L, additional, Green-Lingren, Olivia, additional, Hayden, Robert, additional, Bendapudi, Pavan K, additional, Chute, Donald F, additional, Sise, Meghan E, additional, Jhaveri, Kenar D, additional, Page, Valda D, additional, Abramson, Matthew H, additional, Motwani, Shveta S, additional, Xu, Wenxin, additional, Sehgal, Kartik, additional, Reynolds, Kerry L, additional, Bansal, Anip, additional, Abudayyeh, Ala, additional, and Leaf, David E, additional

Published
2024
Full Text
View/download PDF

20. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis

Author

Moledina, Dennis G., primary, Obeid, Wassim, additional, Smith, Rex N., additional, Rosales, Ivy, additional, Sise, Meghan E., additional, Moeckel, Gilbert, additional, Kashgarian, Michael, additional, Kuperman, Michael, additional, Campbell, Kirk N., additional, Lefferts, Sean, additional, Meliambro, Kristin, additional, Bitzer, Markus, additional, Perazella, Mark A., additional, Luciano, Randy L., additional, Pober, Jordan S., additional, Cantley, Lloyd G., additional, Colvin, Robert B., additional, Wilson, F. Perry, additional, and Parikh, Chirag R., additional

Published
2024
Full Text
View/download PDF

21. Risk Factors for Severe Hypertension and Proteinuria After Treatment With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors Among Patients With Cancer

Author

Hanna, Paul E., primary, Anumolu, Rajesh K., additional, Motwani, Shveta S., additional, Chen, Kevin L., additional, Katz-Agranov, Nurit, additional, Green-Lingren, Olivia, additional, Yilmam, Osman A., additional, Jhaveri, Kenar D., additional, Kitchlu, Abhijat, additional, Kala, Jaya, additional, Sise, Meghan E., additional, and Gupta, Shruti, additional

Published
2024
Full Text
View/download PDF

26. Modulation of the Association Between Age and Death by Risk Factor Burden in Critically Ill Patients With COVID-19

Author

Sunderraj, Ashwin, Cho, Chloe, Cai, Xuan, Gupta, Shruti, Mehta, Rupal, Isakova, Tamara, Leaf, David E., Srivastava, Anand, Walther, Carl P., Anumudu, Samaya J., Arunthamakun, Justin, Kopecky, Kathleen F., Milligan, Gregory P., McCullough, Peter A., Nguyen, Thuy-Duyen, Shaefi, Shahzad, Krajewski, Megan L., Shankar, Sidharth, Pannu, Ameeka, Valencia, Juan D., Waikar, Sushrut S., Kibbelaar, Zoe A., Athavale, Ambarish M., Hart, Peter, Upadhyay, Shristi, Vohra, Ishaan, Oyintayo, Ajiboye, Green, Adam, Rachoin, Jean-Sebastien, Schorr, Christa A., Shea, Lisa, Edmonston, Daniel L., Mosher, Christopher L., Shehata, Alexandre M., Cohen, Zaza, Allusson, Valerie, Bambrick-Santoyo, Gabriela, Bhatti, Noor ul aain, Mehta, Bijal, Williams, Aquino, Brenner, Samantha K., Walters, Patricia, Go, Ronaldo C., Rose, Keith M., Hernán, Miguel A., Zhou, Amy M., Kim, Ethan C., Lisk, Rebecca, Chan, Lili, Mathews, Kusum S., Coca, Steven G., Altman, Deena R., Saha, Aparna, Soh, Howard, Hsun Wen, Huei, Bose, Sonali, Leven, Emily A., Wang, Jing G., Mosoyan, Gohar, Nadkarni, Girish N., Pattharanitima, Pattharawin, Gallagher, Emily J., Friedman, Allon N., Guirguis, John, Kapoor, Rajat, Meshberger, Christopher, Kelly, Katherine J., Parikh, Chirag R., Garibaldi, Brian T., Corona-Villalobos, Celia P., Wen, Yumeng, Menez, Steven, Malik, Rubab F., Elena Cervantes, Carmen, Gautam, Samir C., Mallappallil, Mary C., Ouyang, Jie, John, Sabu, Yap, Ernie, Melaku, Yohannes, Mohamed, Ibrahim, Bajracharya, Siddhartha, Puri, Isha, Thaxton, Mariah, Bhattacharya, Jyotsna, Wagner, John, Boudourakis, Leon, Bryant Nguyen, H., Ahoubim, Afshin, Thomas, Leslie F., Sirganagari, Dheeraj Reddy, Guru, Pramod K., Kashani, Kianoush, Tehranian, Shahrzad, Zhou, Yan, Bergl, Paul A., Rodriguez, Jesus, Shah, Jatan A., Gupta, Mrigank S., Kumar, Princy N., Lazarous, Deepa G., Kassaye, Seble G., Melamed, Michal L., Johns, Tanya S., Mocerino, Ryan, Prudhvi, Kalyan, Zhu, Denzel, Levy, Rebecca V., Azzi, Yorg, Fisher, Molly, Yunes, Milagros, Sedaliu, Kaltrina, Golestaneh, Ladan, Brogan, Maureen, Kumar, Neelja, Chang, Michael, Thakkar, Jyotsana, Raichoudhury, Ritesh, Athreya, Akshay, Farag, Mohamed, Schenck, Edward J., Cho, Soo Jung, Plataki, Maria, Alvarez-Mulett, Sergio L., Gomez-Escobar, Luis G., Pan, Di, Lee, Stefi, Krishnan, Jamuna, Whalen, William, Charytan, David, Macina, Ashley, Chaudhry, Sobaata, Wu, Benjamin, Modersitzki, Frank, Srivastava, Anand, Leidner, Alexander S., Martinez, Carlos, Kruser, Jacqueline M., Wunderink, Richard G., Hodakowski, Alexander J., Velez, Juan Carlos Q., Price-Haywood, Eboni G., Matute-Trochez, Luis A., Hasty, Anna E., Mohamed, Muner MB., Avasare, Rupali S., Zonies, David, Leaf, David E., Gupta, Shruti, Sise, Meghan E., Newman, Erik T., Abu Omar, Samah, Pokharel, Kapil K., Sharma, Shreyak, Singh, Harkarandeep, Correa, Simon, Shaukat, Tanveer, Kamal, Omer, Wang, Wei, Yang, Heather, Boateng, Jeffery O., Lee, Meghan, Strohbehn, Ian A., Li, Jiahua, Mueller, Ariel L., Redfern, Roberta E., Cairl, Nicholas S., Naimy, Gabriel, Abu-Saif, Abeer, Hall, Danyell, Bickley, Laura, Rowan, Chris, Madhani-Lovely, Farah, Cruz, Vivian S., Hess, Kristen M., Jacobs, Alanna L., Peev, Vasil, Reiser, Jochen, Byun, John J., Vissing, Andrew, Kapania, Esha M., Post, Zoe, Patel, Nilam P., Hermes, Joy-Marie, Sutherland, Anne K., Patrawalla, Amee, Finkel, Diana G., Danek, Barbara A., Arikapudi, Sowminya, Paer, Jeffrey M., Cangialosi, Peter, Liotta, Mark, Radbel, Jared, Puri, Sonika, Sunderram, Jag, Scharf, Matthew T., Ahmed, Ayesha, Berim, Ilya, Vatson, Jayanth S., Anand, Shuchi, Levitt, Joseph E., Garcia, Pablo, Boyle, Suzanne M., Song, Rui, Zhang, Jingjing, Hoon Woo, Sang, Deng, Xiaoying, Katz-Greenberg, Goni, Senter, Katharine, Sharshir, Moh’d A., Rusnak, Vadym V., Ali, Muhammad Imran, Bansal, Anip, Podoll, Amber S., Chonchol, Michel, Sharma, Sunita, Burnham, Ellen L., Douin, David J., Rashidi, Arash, Hejal, Rana, Judd, Eric, Latta, Laura, Tolwani, Ashita, Albertson, Timothy E., Adams, Jason Y., Chang, Steven Y., Beutler, Rebecca M., Schulze, Carl E., Macedo, Etienne, Rhee, Harin, Liu, Kathleen D., Jotwani, Vasantha K., Koyner, Jay L., Shah, Chintan V., Jaikaransingh, Vishal, Toth-Manikowski, Stephanie M., Joo, Min J., Lash, James P., Neyra, Javier A., Chaaban, Nourhan, Elias, Madona, Ahmad, Yahya, Iardino, Alfredo, Au, Elizabeth H., Sharma, Jill H., Anne Sosa, Marie, Taldone, Sabrina, Contreras, Gabriel, De La Zerda, David, Gershengorn, Hayley B., Shukla, Bhavarth, Fornoni, Alessia, Ferreira, Tanira, Hayek, Salim S., Blakely, Pennelope, Berlin, Hanna, Azam, Tariq U., Shadid, Husam, Pan, Michael, O’ Hayer, Patrick, Meloche, Chelsea, Feroze, Rafey, Kaakati, Rayan, Perry, Danny, Bitar, Abbas, Anderson, Elizabeth, Padalia, Kishan J., Donnelly, John P., Admon, Andrew J., Flythe, Jennifer E., Tugman, Matthew J., Chang, Emily H., Brown, Brent R., Leonberg-Yoo, Amanda K., Spiardi, Ryan C., Miano, Todd A., Roche, Meaghan S., Vasquez, Charles R., Bansal, Amar D., Ernecoff, Natalie C., Kapoor, Sanjana, Verma, Siddharth, Chen, Huiwen, Kovesdy, Csaba P., Molnar, Miklos Z., Azhar, Ambreen, Susan Hedayati, S., Nadamuni, Mridula V., Shastri, Shani, Willett, Duwayne L., Short, Samuel A.P., Renaghan, Amanda D., Enfield, Kyle B., Bhatraju, Pavan K., Bilal Malik, A., Semler, Matthew W., Vijayan, Anitha, Mariyam Joy, Christina, Li, Tingting, Goldberg, Seth, Kao, Patricia F., Schumaker, Greg L., Goyal, Nitender, Faugno, Anthony J., Schumaker, Greg L., Hsu, Caroline M., Tariq, Asma, Meyer, Leah, Kshirsagar, Ravi K., Weiner, Daniel E., Jose, Aju, Christov, Marta, Griffiths, Jennifer, Gupta, Sanjeev, Kapoor, Aromma, Wilson, Perry, Arora, Tanima, and Ugwuowo, Ugochukwu

Published
2022
Full Text
View/download PDF

28. Filter clotting with continuous renal replacement therapy in COVID-19

Author

Endres, Paul, Rosovsky, Rachel, Zhao, Sophia, Krinsky, Scott, Percy, Shananssa, Kamal, Omer, Roberts, Russel J., Lopez, Natasha, Sise, Meghan E., Steele, David J. R., Lundquist, Andrew L., Rhee, Eugene P., Hibbert, Kathryn A., Hardin, C. Corey, Mc Causland, Finnian R., Czarnecki, Peter G., Mutter, Walter, Tolkoff-Rubin, Nina, and Allegretti, Andrew S.

Published
2021
Full Text
View/download PDF

29. Sarcopenia, adiposity and large discordance between cystatin C and creatinine‐based estimated glomerular filtration rate in patients with cancer.

Author

Hanna, Paul E., Ouyang, Tianqi, Tahir, Ismail, Katz‐Agranov, Nurit, Wang, Qiyu, Mantz, Lea, Strohbehn, Ian, Moreno, Daiana, Harden, Destiny, Dinulos, James E., Cosar, Duru, Seethapathy, Harish, Gainor, Justin F., Shah, Sachin J., Gupta, Shruti, Leaf, David E., Fintelmann, Florian J., and Sise, Meghan E.

Published
2024
Full Text
View/download PDF

30. Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanoma.

Author

Mistry, Kavita, Zhao, Sophia, Strohbehn, Ian, Wang, Qiyu, Hanna, Paul, Strohbehn, Samuel, Katz-Agranov, Nurit, Sullivan, Ryan J, and Sise, Meghan E

Subjects
BRAF genes, KIDNEY physiology, KIDNEY transplantation, INTERSTITIAL nephritis, MELANOMA
Abstract

This article discusses the potential risk of acute kidney injury (AKI) and chronic kidney disease (CKD) in patients receiving BRAF/MEK inhibitor therapy for melanoma. Real-world data showed higher rates of AKI compared to clinical trials. The study found that patients who received BRAF/MEK inhibitors had a higher risk of CKD compared to a group of patients who underwent surgical resection alone. The study suggests that CKD is an important comorbidity in melanoma patients and further research is needed to understand the mechanisms and develop therapies to slow kidney function decline in these patients. [Extracted from the article]

Published
2024
Full Text
View/download PDF

35. Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function

Author

Saxena, Varun, Koraishy, Farrukh M, Sise, Meghan E, Lim, Joseph K, Schmidt, Monica, Chung, Raymond T, Liapakis, Annmarie, Nelson, David R, Fried, Michael W, Terrault, Norah A, and HCV‐TARGET

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Liver Disease, Kidney Disease, Hepatitis, Clinical Research, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Renal and urogenital, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Antiviral Agents, Databases, Factual, Drug Therapy, Combination, Europe, Female, Glomerular Filtration Rate, Hepacivirus, Hepatitis C, Chronic, Humans, Liver Cirrhosis, Longitudinal Studies, Male, Middle Aged, Multivariate Analysis, North America, Regression Analysis, Renal Dialysis, Renal Insufficiency, Chronic, Simeprevir, Sofosbuvir, Sustained Virologic Response, Young Adult, decompensated cirrhosis, haemodialysis, liver transplantation, sustained virologic response, HCV-TARGET, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsRenal clearance is the major elimination pathway for sofosbuvir (SOF). We assessed the safety and efficacy of SOF-containing regimens in patients with varying baseline estimated glomerular filtration rate (eGFR).MethodsHCV-TARGET database is a multicentre, longitudinal 'real-world' treatment cohort.ResultsA total of 1789 patients [genotypes 1 (72%), 2 (17%) 3 (9%), 4-6 (2%)] had baseline eGFR determination: 73 with eGFR≤45 (18 with eGFR≤30, 5 on dialysis) were compared to 1716 with eGFR>45 ml/min/1.73 m(2) . Patients with baseline eGFR≤45 vs. >45 differed in being female (55% vs. 36%), age ≥65 years (24% vs. 16%), Black race (22% vs. 12%), having cirrhosis with decompensation (73% vs. 24%) and being post-transplant (49% vs. 10%), all P < 0.05. All patients with eGFR≤45 were treated with SOF 400 mg/day (including those on haemodialysis) and had median starting ribavirin (RBV) dose of 800 mg (IQR: 400-1200). Sustained virologic response (SVR) frequencies were similar across eGFR groups, ranging from 82-83%. Patients with eGFR ≤45 more frequently experienced anaemia, worsening renal function and serious AEs (all P < 0.05), and these associations persisted when limiting analysis to RBV-free regimens. Patients with baseline eGFR≤30 and eGFR 31-45 had similar frequencies of efficacy and safety outcomes.ConclusionsSustained viral clearance was achieved in 83% of patients with renal impairment (eGFR ≤45 ml/min/1.73 m(2) ) treated with SOF-containing regimens. However, these patients had higher rates of anaemia, worsening renal dysfunction and serious adverse events regardless of use of RBV. Patient with renal impairment require close monitoring and should be treated by providers extensively experienced with SOF-containing regimens.

Published
2016

36. Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline

Author

Awan, Ahmed Arslan Yousuf, primary, Berenguer, Marina C., additional, Bruchfeld, Annette, additional, Fabrizi, Fabrizio, additional, Goldberg, David S., additional, Jia, Jidong, additional, Kamar, Nassim, additional, Mohamed, Rosmawati, additional, Pessôa, Mário Guimarães, additional, Pol, Stanislas, additional, Sise, Meghan E., additional, Balk, Ethan M., additional, Gordon, Craig E., additional, Adam, Gaelen, additional, Cheung, Michael, additional, Earley, Amy, additional, Martin, Paul, additional, and Jadoul, Michel, additional

Published
2023
Full Text
View/download PDF

37. Pyelonephritis is an Underrecognized Cause of CKD in Patients With Orthotopic Ileal Neobladder Substitution

Author

Wang, Qiyu, primary, Seethapathy, Rituvanthikaa, additional, Ouyang, Tianqi, additional, Strohbehn, Ian A., additional, Katz-Agranov, Nurit, additional, Hanna, Paul, additional, Madken, Mohit, additional, Seethapathy, Harish, additional, Gupta, Shruti, additional, Heller, Howard M., additional, Wszolek, Matthew, additional, Steele, David, additional, Klepeis, Veronica E., additional, Rennke, Helmut, additional, and Sise, Meghan E., additional

Published
2023
Full Text
View/download PDF

38. Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation

Author

Vergara-Cadavid, Juliana, Johnson, P. Connor, Kim, Haesook T., Yi, Alisha, Sise, Meghan E., Leaf, David E., Hanna, Paul E., Ho, Vincent T., Cutler, Corey S., Antin, Joseph H., Gooptu, Mahasweta, Kelkar, Amar H., Wells, Sophia L., Nikiforow, Sarah, Koreth, John, Romee, Rizwan, Soiffer, Robert J., Shapiro, Roman M., and Gupta, Shruti

Published
2023
Full Text
View/download PDF

39. AKI treated with kidney replacement therapy in critically Ill allogeneic hematopoietic stem cell transplant recipients

Author

Kim, Helena, primary, Ali, Rafia, additional, Short, Samuel, additional, Kaunfer, Sarah, additional, Krishnamurthy, Shobana, additional, Durai, Lavanya, additional, Yilmam, Osman, additional, Shenoy, Tushar, additional, Monson, Audrey E., additional, Thomas, Charlotte, additional, Park, Isabel, additional, Martini, Dylan, additional, Newcomb, Richard, additional, Shapiro, Roman M., additional, Soiffer, Robert J., additional, DeFilipp, Zachariah, additional, Baron, Rebecca M., additional, Gupta, Shruti, additional, Sise, Meghan E., additional, and Leaf, David E., additional

Published
2023
Full Text
View/download PDF

41. Machine Learning Prediction of Death in Critically Ill Patients With Coronavirus Disease 2019

Author

Churpek, Matthew M., Gupta, Shruti, Spicer, Alexandra B., Hayek, Salim S., Srivastava, Anand, Chan, Lili, Melamed, Michal L., Brenner, Samantha K., Radbel, Jared, Madhani-Lovely, Farah, Bhatraju, Pavan K., Bansal, Anip, Green, Adam, Goyal, Nitender, Shaefi, Shahzad, Parikh, Chirag R., Semler, Matthew W., Leaf, David E., Walther, Carol P., Anumudu, Samaya J., Arunthamakun, Justin, Kopecky, Kathleen F., Milligan, Gregory P., McCullough, Peter A., Nguyen, ThuyDuyen, Shaefi, Shahzad, Krajewski, Megan L., Shankar, Sidharth, Pannu, Ameeka, Valencia, Juan D., Waikar, Sushrut S., Kibbelaar, Zoe A., Athavale, Ambarish M., Hart, Peter, Ajiboye, Oyintayo, Itteera, Matthew, Green, Adam, Rachoin, Jean-Sebastien, Schorr, Christa A., Shea, Lisa, Edmonston, Daniel L., Mosher, Christopher L., Shehata, Alexandre M., Cohen, Zaza, Allusson, Valerie, Bambrick-Santoyo, Gabriela, Bhatti, Noor ul aain, Metha, Bijal, Williams, Aquino, Brenner, Samantha K., Walters, Patricia, Go, Ronaldo C., Rose, Keith M., Hernán, Miguel A., Zhou, Amy M., Kim, Ethan C., Lisk, Rebecca, Chan, Lili, Mathews, Kusum S., Coca, Steven G., Altman, Deena R., Saha, Aparna, Soh, Howard, Wen, Huei Hsun, Bose, Sonali, Leven, Emily, Wang, Jing G., Mosoyan, Gohar, Nadkarni, Girish N., Friedman, Allon N., Guirguis, John, Kapoor, Rajat, Meshberger, Christopher, Parikh, Chirag R., Garibaldi, Brian T., Corona-Villalobos, Celia P., Wen, Yumeng, Menez, Steven, Malik, Rubab F., Cervantes, Carmen Elena, Gautam, Samir C., Chang, Crystal, Nguyen, H. Bryant, Ahoubim, Afshin, Thomas, Leslie F., Guru, Pramod K., Bergl, Paul A., Zhou, Yan, Rodriguez, Jesus, Shah, Jatan A., Gupta, Mrigank S., Kumar, Princy N., Lazarous, Deepa G., Kassaye, Seble G., Melamed, Michal L., Johns, Tanya S., Mocerino, Ryan, Prudhvi, Kalyan, Zhu, Denzel, Levy, Rebecca V., Azzi, Yorg, Fisher, Molly, Yunes, Milagros, Sedaliu, Kaltrina, Golestaneh, Ladan, Brogan, Maureen, Thakkar, Jyotsana, Kumar, Neelja, Ross, Michael J., Chang, Michael, Raichoudhury, Ritesh, Schenck, Edward J., Cho, Soo Jung, Plataki, Maria, Alvarez-Mulett, Sergio L., Gomez-Escobar, Luis G., Pan, Di, Lee, Stefi, Krishnan, Jamuna, Whalen, William, Charytan, David, Macina, Ashley, Ross, Daniel W., Srivastava, Anand, Leidner, Alexander S., Martinez, Carlos, Kruser, Jacqueline M., Wunderink, Richard G., Hodakowski, Alexander J., Velez, Juan Carlos Q., Price-Haywood, Eboni G., Matute-Trochez, Luis A., Hasty, Anna E., Mohamed, Muner MB., Avasare, Rupali S., Zonies, David, Leaf, David E., Gupta, Shruti, Baron, Rebecca M., Sise, Meghan E., Newman, Erik T., Omar, Samah Abu, Pokharel, Kapil K., Sharma, Shreyak, Singh, Harkarandeep, Gaviria, Simon Correa, Shaukat, Tanveer, Kamal, Omer, Wang, Wei, Yang, Heather, Boateng, Jeffery O., Lee, Meghan, Strohbehn, Ian A., Li, Jiahua, Muhsin, Saif A., Mandel, Ernest I., Mueller, Ariel L., Cairl, Nicholas S., Madhani-Lovely, Farah, Rowan, Chris, Madhai-Lovely, Farah, Peev, Vasil, Reiser, Jochen, Byun, John J., Vissing, Andrew, Kapania, Esha M., Post, Zoe, Patel, Nilam P., Hermes, Joy-Marie, Sutherland, Anne K., Patrawalla, Amee, Finkel, Diana G., Danek, Barbara A., Arikapudi, Sowminya, Paer, Jeffrey M., Radbel, Jared, Puri, Sonika, Sunderram, Jag, Scharf, Matthew T., Ahmed, Ayesha, Berim, Ilya, Vatson, Jayanth, Anand, Shuchi, Levitt, Joseph E., Garcia, Pablo, Boyle, Suzanne M., Song, Rui, Zhang, Jingjing, Sharshir, Moh’d A., Rusnak, Vadym V., Bansal, Anip, Podoll, Amber S., Chonchol, Michel, Sharma, Sunita, Burnham, Ellen L., Rashidi, Arash, Hejal, Rana, Judd, Eric, Latta, Laura, Tolwani, Ashita, Albertson, Timothy E., Adams, Jason Y., Chang, Steven Y., Beutler, Rebecca M., Schulze, Carl E., Macedo, Etienne, Rhee, Harin, Liu, Kathleen D., Jotwani, Vasantha K., Koyner, Jay L., Shah, Chintan V., Jaikaransingh, Vishal, Toth-Manikowski, Stephanie M., Joo, Min J., Lash, James P., Neyra, Javier A., Chaaban, Nourhan, Iardino, Alfredo, Au, Elizabeth H., Sharma, Jill H., Anne Sosa, Marie, Taldone, Sabrina, Contreras, Gabriel, De La Zerda, David, Gershengorn, Hayley B., Hayek, Salim S., Blakely, Pennelope, Berlin, Hanna, Azam, Tariq U., Shadid, Husam, Pan, Michael, Hayer, Patrick O’, Meloche, Chelsea, Feroze, Rafey, Padalia, Kishan J., Leya, Jeff, Donnelly, John P., Admon, Andrew J., Flythe, Jennifer E., Tugman, Matthew J., Brown, Brent R., Leonberg-Yoo, Amanda K., Spiardi, Ryan C., Miano, Todd A., Roche, Meaghan S., Vasquez, Charles R., Bansal, Amar D., Ernecoff, Natalie C., Kovesdy, Csaba P., Molnar, Miklos Z., Hedayati, S. Susan, Nadamuni, Mridula V., Khan, Sadaf S., Willett, Duwayne L., Short, Samuel A.P., Renaghan, Amanda D., Bhatraju, Pavan, Malik, A. Bilal, Semler, Matthew W., Vijayan, Anitha, Mariyam Joy, Christina, Li, Tingting, Goldberg, Seth, Kao, Patricia F., Schumaker, Greg L., Goyal, Nitender, Faugno, Anthony J., Schumaker, Greg L., Hsu, Caroline M., Tariq, Asma, Meyer, Leah, Christov, Marta, Wilson, Francis P., Arora, Tanima, and Ugwuowo, Ugochukwu

Published
2021
Full Text
View/download PDF

42. Medication-Related Adverse Events and Discordancies in Cystatin C–Based vs Serum Creatinine–Based Estimated Glomerular Filtration Rate in Patients With Cancer

Author

Hanna, Paul E., primary, Wang, Qiyu, additional, Strohbehn, Ian A., additional, Moreno, Daiana, additional, Harden, Destiny, additional, Ouyang, Tianqi, additional, Katz-Agranov, Nurit, additional, Seethapathy, Harish, additional, Reynolds, Kerry L., additional, Gupta, Shruti, additional, Leaf, David E., additional, and Sise, Meghan E., additional

Published
2023
Full Text
View/download PDF

48. Kidney Function in Patients with Ovarian Cancer Treated with Poly (ADP-ribose) polymerase (PARP) Inhibitors

Author

Gupta, Shruti, primary, Hanna, Paul E, additional, Ouyang, Tianqi, additional, Yamada, Karla Sofia, additional, Sawtell, Rani, additional, Wang, Qiyu, additional, Katz-Agranov, Nurit, additional, Feghali, Lea, additional, Krasner, Carolyn N, additional, Bouberhan, Sara, additional, Castro, Cesar M, additional, and Sise, Meghan E, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results